相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
Sigbjorn Smeland et al.
EUROPEAN JOURNAL OF CANCER (2019)
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
Florence Duffaud et al.
LANCET ONCOLOGY (2019)
Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial
Lu Xie et al.
ONCOLOGIST (2019)
Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3
Bingxin Zheng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
Bingxin Zheng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Sandra P. D'Angelo et al.
LANCET ONCOLOGY (2018)
Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis
Xin Huang et al.
JOURNAL OF CANCER (2018)
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
Wenfeng Fang et al.
LANCET ONCOLOGY (2018)
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
Yayan T. Sundara et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
Ghayathri Jeyakumar et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R. Ramjiawan et al.
ANGIOGENESIS (2017)
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
Pratistha Koirala et al.
SCIENTIFIC REPORTS (2016)
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan S. Bielack et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
Giovanni Grignani et al.
LANCET ONCOLOGY (2015)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
Osteosarcoma treatment - Where do we stand? A state of the art review
Anja Luetke et al.
CANCER TREATMENT REVIEWS (2014)
Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma
Fariba Navid et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis
Marnie Collins et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the Interchangeability of PPS and KPS in Prognostic Tools
Ingrid de Kock et al.
JOURNAL OF PALLIATIVE CARE (2013)
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
G. Grignani et al.
ANNALS OF ONCOLOGY (2012)
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
Eric Tartour et al.
CANCER AND METASTASIS REVIEWS (2011)
Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
Kim Cocks et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy
Andrea Nicolini et al.
CANCER LETTERS (2007)
分享论文
